Position of the Transparency Council – Ultomiris (ravulizumab)

At its meeting on 5 August 2024, the Transparency Council adopted position No. 82/2024 on the evaluation of the drug Ultomiris (ravulizumab) within the framework of the drug program: “Treatment of patients with generalized form of myasthenia gravis (G70.0)”

Publication of the position >>